|
|
Organon and Co (NYSE: OGN) |
|
Price: $13.7800
$0.01 
0.073%
|
| Day's High:
| $13.779999732971191
| Week Perf:
| 0.15 %
|
| Day's Low: |
$ 13.76 |
30 Day Perf: |
1.7 % |
| Volume (M): |
4,872,466 |
52 Wk High: |
$ 13.78 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$10.05 |
| Open: |
$13.76 |
52 Wk Low: |
$5.69 |
|
|
| Market Capitalization (Millions $) |
3,727 |
| Shares
Outstanding (Millions) |
270 |
| Employees |
10,000 |
| Revenues (TTM) (Millions $) |
6,139 |
| Net Income (TTM) (Millions $) |
-5 |
| Cash Flow (TTM) (Millions $) |
569 |
| Capital Exp. (TTM) (Millions $) |
312 |
Business Description
Organon and Co is a pharmaceutical company that was founded nearly a century and a half ago in the Netherlands. It has since grown into a global biopharmaceutical company that specializes in developing and manufacturing innovative medicines to improve patients' lives.
The company's name, Organon, refers to the Greek word "organon," which means "tool" or "instrument." This reflects Organon's mission to create tools and solutions to help physicians and healthcare providers feel confident in their treatment decisions.
Organon and Co's focus is on three main areas: Women's Health, Biosimilars, and Established Brands. The Women's Health division focuses on developing and providing solutions for women's health and wellness, including contraception, infertility, and menopause treatments. The Biosimilars division aims to provide access to high-quality, affordable biosimilars, helping to increase patient access to life-saving biologic medicines. The Established Brands division focuses on providing innovative solutions to improve the health and well-being of patients, including treatments for cardiovascular disease, migraine, and schizophrenia.
Organon and Co is committed to advancing science and research to better understand and meet patients' needs. They invest heavily in research and development, focusing on developing innovative medicines and treatments using state-of-the-art technologies.
In addition to its focus on innovative research and development, Organon and Co is committed to social responsibility and sustainability. They have created programs and initiatives to promote health and wellness in underserved communities, reduce their environmental impact, and improve patient access to medicines.
Overall, Organon and Co's mission is to improve patients' lives by providing innovative solutions and treatments that address pressing medical needs. They are committed to advancing science and research, promoting social responsibility, and ensuring patient access to life-saving medicines.
Company Address: 30 Hudson Street, Floor 33 Jersey City, 7302 NJ
Company Phone Number: 430-6900 Stock Exchange / Ticker: NYSE OGN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Mon, Sep 22 2025 2:55 AM UTC
In a significant development for the pharmaceutical sector, the European Commission (EC) has granted market authorization for BILDYOS and BILPREVDA, two biosimilar versions of Denosumab sourced from Henlius Biotech, Inc. and Organon. These approvals open up new avenues for treatment in various medical indications previously dominated by the original products, PROLIA and XGEV...
|
| Business Update
Published Sun, Sep 21 2025 6:55 PM UTC
In a significant stride for the biotechnology sector, the European Commission (EC) has granted market authorization for two new biosimilars, BILDYOS and BILPREVDA, developed by Shanghai Henlius Biotech, Inc. and Organon. These biosimilars are targeted at Denosumab, the active ingredient found in established treatments like Prolia and Xgeva. This approval is not just a routi...
|
| Business Update
Published Sun, Sep 21 2025 6:42 PM UTC
In a significant development within the pharmaceutical industry, the European Commission recently granted marketing authorization for two biosimilars, BILDYOS and BILPREVDA, both of which are versions of the established drug Denosumab. Developed by Henlius Biotech, based in Shanghai, and Organon, headquartered in Jersey City, these biosimilars serve as alternatives to Prolia...
|
| Announcement
Published Thu, Jul 10 2025 1:59 PM UTC
Organon & Co., a notable player in the biopharmaceutical sector, is currently facing significant legal challenges as a class action lawsuit has been filed against the company. This litigation, spearheaded by prominent law firms Pomerantz LLP and Levi & Korsinsky LLP, seeks to address alleged investment losses experienced by shareholders. As the company finds itself in the l...
|
| Announcement
Published Thu, Jun 12 2025 8:52 AM UTC
Organon Shareholder Alert: Investors Urged to Act Amid Class Action Lawsuit Due to Underperformance In a noteworthy development for shareholders of Organon & Co. (NYSE: OGN), ClaimsFiler has issued a reminder to investors who have suffered losses exceeding $100,000 to file lead plaintiff applications in an ongoing class action lawsuit. The deadline for this filing is set for...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
0.77 $ |
| Revenues (TTM) |
22.7 $
|
| Cash Flow (TTM) |
2.1 $ |
| Cash |
4.19 $
|
| Book Value |
3.72 $
|
| Dividend (TTM) |
0.08 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
613,900 |
| Net
Income per Employee (TTM) |
-500 |
| Receivable Turnover Ratio (TTM) |
4.31 |
| Inventory Turnover Ratio (TTM) |
2.06 |
| Asset Turnover Ratio (TTM) |
0.47 |
|
|
| Per Share |
|
| Earnings (TTM) |
0.77 $
|
| Revenues (TTM) |
22.7 $ |
| Cash Flow (TTM) |
2.1 $ |
| Cash |
4.19 $
|
| Book Value |
3.72 $ |
| Dividend (TTM) |
0.08 $ |
|
|
| |
| Nexplanon Implanon NXT |
|
 13.77 % |
of total Revenue |
| Follistim AQ |
|
4.18 % |
of total Revenue |
| NuvaRing |
|
1.64 % |
of total Revenue |
| Ganirelix Acetate Injection |
|
1.78 % |
of total Revenue |
| Marvelon Mercilon |
|
1.78 % |
of total Revenue |
| Jada |
|
0.34 % |
of total Revenue |
| Other Women s Health |
|
3.15 % |
of total Revenue |
| Renflexis |
|
3.9 % |
of total Revenue |
| Hadlima |
|
4.59 % |
of total Revenue |
| Ontruzant |
|
0.34 % |
of total Revenue |
| Brenzys |
|
1.37 % |
of total Revenue |
| Other Biosimilars |
|
1.64 % |
of total Revenue |
| Atozet |
|
5.82 % |
of total Revenue |
| Zetia |
|
5.96 % |
of total Revenue |
| Cozaar Hyzaar |
|
3.9 % |
of total Revenue |
| Vytorin |
|
1.44 % |
of total Revenue |
| Rosuzet |
|
0.41 % |
of total Revenue |
| Other Cardiovascular |
|
1.92 % |
of total Revenue |
| Singulair |
|
2.74 % |
of total Revenue |
| Nasonex |
|
4.45 % |
of total Revenue |
| Dulera |
|
2.4 % |
of total Revenue |
| Clarinex |
|
2.12 % |
of total Revenue |
| Other Respiratory |
|
0.82 % |
of total Revenue |
| Arcoxia |
|
4.04 % |
of total Revenue |
| Fosamax |
|
1.99 % |
of total Revenue |
| Diprospan |
|
2.4 % |
of total Revenue |
| Vtama |
|
1.71 % |
of total Revenue |
| Other Non-Opiod Pain Bone and Dermatology |
|
4.66 % |
of total Revenue |
| Propecia |
|
2.05 % |
of total Revenue |
| Emgality |
|
3.7 % |
of total Revenue |
| Proscar |
|
1.78 % |
of total Revenue |
| Other |
|
1.58 % |
of total Revenue |
| U S |
|
24.52 % |
of total Revenue |
| U S Nexplanon Implanon NXT |
|
8.7 % |
of total Revenue |
| U S Follistim AQ |
|
1.44 % |
of total Revenue |
| U S NuvaRing |
|
0.41 % |
of total Revenue |
| U S Ganirelix Acetate Injection |
|
0.14 % |
of total Revenue |
| U S Jada |
|
0.34 % |
of total Revenue |
| U S Other Women s Health |
|
1.16 % |
of total Revenue |
| U S Renflexis |
|
2.88 % |
of total Revenue |
| U S Hadlima |
|
3.49 % |
of total Revenue |
| U S Ontruzant |
|
0.27 % |
of total Revenue |
| U S Other Biosimilars |
|
0.75 % |
of total Revenue |
| U S Zetia |
|
0.07 % |
of total Revenue |
| U S Cozaar Hyzaar |
|
0.14 % |
of total Revenue |
| U S Vytorin |
|
0.07 % |
of total Revenue |
| U S Other Cardiovascular |
|
0.07 % |
of total Revenue |
| U S Singulair |
|
0.14 % |
of total Revenue |
| U S Dulera |
|
1.58 % |
of total Revenue |
| U S Clarinex |
|
0.07 % |
of total Revenue |
| U S Other Respiratory |
|
0.75 % |
of total Revenue |
| U S Vtama |
|
1.58 % |
of total Revenue |
| U S Other Non-Opiod Pain Bone and Dermatology |
|
0.21 % |
of total Revenue |
| U S Propecia |
|
0.07 % |
of total Revenue |
| U S Other |
|
0.21 % |
of total Revenue |
| Int l |
|
75.48 % |
of total Revenue |
| Int l Nexplanon Implanon NXT |
|
5.07 % |
of total Revenue |
| Int l Follistim AQ |
|
2.67 % |
of total Revenue |
| Int l NuvaRing |
|
1.23 % |
of total Revenue |
| Int l Ganirelix Acetate Injection |
|
1.64 % |
of total Revenue |
| Int l Marvelon Mercilon |
|
1.78 % |
of total Revenue |
| Int l Other Women s Health |
|
2.05 % |
of total Revenue |
| Int l Renflexis |
|
1.03 % |
of total Revenue |
| Int l Hadlima |
|
1.1 % |
of total Revenue |
| Int l Ontruzant |
|
0.07 % |
of total Revenue |
| Int l Brenzys |
|
1.37 % |
of total Revenue |
| Int l Other Biosimilars |
|
0.89 % |
of total Revenue |
| Int l Atozet |
|
5.82 % |
of total Revenue |
| Int l Zetia |
|
5.89 % |
of total Revenue |
| Int l Cozaar Hyzaar |
|
3.77 % |
of total Revenue |
| Int l Vytorin |
|
1.37 % |
of total Revenue |
| Int l Rosuzet |
|
0.41 % |
of total Revenue |
| Int l Other Cardiovascular |
|
1.85 % |
of total Revenue |
| Int l Singulair |
|
2.6 % |
of total Revenue |
| Int l Nasonex |
|
4.45 % |
of total Revenue |
| Int l Dulera |
|
0.82 % |
of total Revenue |
| Int l Clarinex |
|
2.05 % |
of total Revenue |
| Int l Other Respiratory |
|
0.07 % |
of total Revenue |
| Int l Arcoxia |
|
4.04 % |
of total Revenue |
| Int l Fosamax |
|
1.99 % |
of total Revenue |
| Int l Diprospan |
|
2.4 % |
of total Revenue |
| Int l Vtama |
|
0.14 % |
of total Revenue |
| Int l Other Non-Opiod Pain Bone and Dermatology |
|
4.45 % |
of total Revenue |
| Int l Propecia |
|
1.92 % |
of total Revenue |
| Int l Emgality |
|
3.7 % |
of total Revenue |
| Int l Proscar |
|
1.78 % |
of total Revenue |
| Int l Other |
|
5.82 % |
of total Revenue |
| United States |
|
24.52 % |
of total Revenue |
| Europe and Canada |
|
28.22 % |
of total Revenue |
| Asia Pacific and Japan |
|
15.48 % |
of total Revenue |
| China |
|
13.29 % |
of total Revenue |
| Latin America Middle East Russia and Africa |
|
16.92 % |
of total Revenue |
| |
On October 9 2024 the Organon And Co provided following guidance
nnOrganon and Co. to Announce Third Quarter 2024 Earnings and Host Investor Call on October 31, 2024nn
nnJERSEY CITY, N.J.nn – Organon (NYSE: OGN), a global leader in healthcare dedicated to women's health, is set to release its financial results for the third quarter of 2024 on October 31, 2024. The company will hold a webcast and conference call that morning at 8:30 a.m. EDT to discuss the results in detail.
In its financial guidance, Organon anticipates incurring a milestone expense of $51 million during the third quarter, which is expected to have a notable effect on the company's earnings. Specifically, this expense is projected to reduce both Generally Accepted Accounting Principle...
|
|
|
2.68% 